For additional information about CryoLife, visit CryoLife's website, www.cryolife.com.
CRYOLIFE, INC. AND SUBSIDIARIESFinancial Highlights(In thousands, except per share data) Three Months EndedMarch 31,20132012(Unaudited)Revenues:Products$
16,454Preservation services15,67715,659Other63188Total revenues35,53632,301Cost of products and preservation services:Products3,4652,513Preservation services8,7958,496Total cost of products and preservation services12,26011,009Gross margin23,27621,292Operating expenses:General, administrative, and marketing17,97717,970Research and development1,9881,693Total operating expenses19,96519,663Operating income3,3111,629Interest expense5065Interest income(2)(2)Other expense (income), net219(15)Income before income taxes3,0441,581Income tax expense852590Net income$2,192$991Income per common share:Basic$0.08$0.04Diluted$0.08$0.04Dividends declared per share$0.025$--Weighted-average common shares outstanding:Basic26,86127,180Diluted27,48827,530
CRYOLIFE, INC. AND SUBSIDIARIESFinancial Highlights(In thousands) Three Months EndedMarch 31,20132012(Unaudited)Products:BioGlue and BioFoam$
13,696PerClot864644Revascularization technologies2,1912,114HeRO Graft1,277--Total products19,79616,454
Preservation services:Cardiac tissue6,6457,080Vascular tissue9,0328,579Total preservation services15,67715,659Other63188Total revenues$35,536$32,301Revenues:U.S.$
25,287International8,9597,014Total revenues$35,536$32,301March 31,December 31,20132012(Unaudited)(Audited)Cash, cash equivalents, and restricted cash and securities$
18,332Total current assets73,74877,503Total assets153,716157,156Total current liabilities16,58321,430Total liabilities24,73429,044Shareholders' equity128,982128,112
|SOURCE CryoLife, Inc.|
Copyright©2012 PR Newswire.
All rights reserved